Akoya Biosciences, Inc. (AKYA)
| Market Cap | 74.23M |
| Revenue (ttm) | 81.67M |
| Net Income (ttm) | -55.37M |
| Shares Out | 49.82M |
| EPS (ttm) | -1.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 97,291 |
| Open | 1.450 |
| Previous Close | 1.450 |
| Day's Range | 1.425 - 1.515 |
| 52-Week Range | 1.390 - 4.890 |
| Beta | 1.32 |
| Analysts | Buy |
| Price Target | 3.26 (+118.79%) |
| Earnings Date | Mar 17, 2025 |
About AKYA
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-em... [Read more]
Financial Performance
In 2024, Akoya Biosciences's revenue was $81.67 million, a decrease of -15.48% compared to the previous year's $96.63 million. Losses were -$55.37 million, -12.57% less than in 2023.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AKYA stock is "Buy." The 12-month stock price forecast is $3.26, which is an increase of 118.79% from the latest price.
News
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
CHARLOTTE, N.C.--(BUSINESS WIRE)--Tikvah Management LLC (together with its affiliates, “Tikvah” or “we”), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. (Nasdaq: QTR...
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) is a holder of 7.47% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX). Kent L...
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results
MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and ...
Kent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”) a holder of 7.25% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today iss...
Kent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences
RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of 5.9% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today hig...
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner
CARLSBAD, Calif.--(BUSINESS WIRE)--Argonaut Manufacturing Services (“Argonaut”), a leading contract development and manufacturing organization serving the biopharma and life sciences industries, and A...
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Bioscience...
Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers
BILLERICA, Mass. and MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Bioscience...
Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions
Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma pat...
Akoya Biosciences, Inc. (AKYA) Q3 2024 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call ...
Akoya Biosciences Reports Third Quarter 2024 Financial Results
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the third quarter ending...
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the thi...
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its...
Akoya Biosciences, Inc. (AKYA) Q2 2024 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Corporate Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Offic...
Akoya Biosciences Reports Second Quarter 2024 Financial Results
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the second quarter endin...
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the sec...
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry h...
Akoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call Transcript
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q1 2024 Earnings Conference Call May 13, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Parti...
Akoya Biosciences Reports First Quarter 2024 Financial Results
MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending ...
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
Leveraging Akoya's market-leading PhenoImager HT platform and clinical development expertise with NeraCare's Immunoprint test and best-in-class clinical data, the partnership will focus on increasing ...
Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlboro...
Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing mo...
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fi...